KẾT QUẢ ĐIỀU TRỊ UNG THƯ BIỂU MÔ TẾ BÀO SÁNG BUỒNG TRỨNG BẰNG PHÁC ĐỒ PACLITAXEL-CARBOPLATIN

Abstract

Objective: To evaluate some clinical and paraclinical characteristics of patients with clear cell ovarian cancer treated with the paclitaxel-carboplatin regimen, the progression-free survival (PFS) of the study group, and the toxicity assessment of the regimen. Method: This was a cluster case study, with a study population of 53 patients with clear cell ovarian cancer treated with the paclitaxel-carboplatin regimen at Vietnam National Cancer Hospital from January 2015 to January 2023. Results: The mean age of the study subjects was 53.2 ± 1.45 years. The most common functional symptom was lower abdominal distension (77.4%), and the most common physical sign was palpable abdominal mass (81.1%). The most frequent sonographic features suggestive of malignancy were irregular wall (45.3%), papillary projection into the cyst (34.0%), and abdominal fluid (32.1%). At the time of diagnosis, 14.6% of patients had normal serum CA 125 levels, and 23.5% had normal serum HE4 levels. According to FIGO staging, the majority of patients were in stage II (41.5%), with the lowest proportion in stage I (15.1%). Stages III and IV had relatively higher proportions (22.6% and 20.8%, respectively). The 3-year progression-free survival rate (PFS) was found to be 64.2%. The 3-year PFS rate decreased progressively across disease stages, with statistically significant differences (p=0.000). Age, ultrasound tumor size, serum CA 125 levels, and serum HE4 levels did not show significant differences in 3-year PFS rates. Commonly encountered adverse effects were leukopenia, anemia, and thrombocytopenia, primarily at grades 1-2. The most common grade 3-4 toxicity was neutropenia (22.7%). Conclusion: The paclitaxel-carboplatin chemotherapy regimen is effective and well-tolerated in the treatment of patients with clear cell ovarian cancer.